Published

Editorial: Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders.

No abstract availability was recorded for this entry.

Open source BibTeX RIS

Bibliographic context

Journal: Frontiers in psychiatry
Date: 2023-01-01
Source: PubMed
DOI: 10.3389/fpsyt.2023.1191970
PubMed: 37252138

Authors

Blest-Hopley G Amit BH O'Neill A Ruffell SGD

Watch author

Derived topics and classifications

psilocybin Safety Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Psychedelic drugs and the law: What’s next?Knowable Magazine · 2024-03-14 Retreat from racism: A psychedelic group experience for racial stress and traumaPsychedelics · 2026-07-30 Integration in classic psychedelic-assisted therapies for mental health conditions: A scoping reviewPsychedelics · 2026-07-26 Psilocybin's effects on obsessive-compulsive behaviors: A systematic review of preclinical and clinical evidencePsychedelics. · 2025-10-27 Gregor Hasler: Three Guiding Questions - How do psychedelics shape the brain? How can they heal psychiatric disorders such as depression and PTSD? How can we ensure their safe and responsible use?Psychedelics. · 2025-09-02 Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: The case for a hybrid group-based delivery modelPsychedelics · 2026-12-01 Psilocybin exerts differential effects on social behavior and inflammation in mice in contexts of activity-based anorexiaPsychedelics. · 2026-02-03 Self-reported improvement in depression, anxiety, and substance use in Spanish-speakers after a memorable psychedelic experiencePsychedelics · 2025-11-20